Marimed (MRMD) Net Margin (2011 - 2026)

Marimed (MRMD) has reported Net Margin for 16 consecutive years, with 8.52% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin fell 499.0% year-over-year to 8.52% in Q2 2026; TTM through Jun 2026 was 9.11%, a 117.0% increase from a year earlier, with the FY2025 full-year figure at 9.04%, down 116.0% from the prior year.
• Net Margin was 8.52% for Q2 2026 at Marimed, up from 9.54% in the prior quarter.
• Over five years, Net Margin peaked at 13.56% in Q1 2022 and troughed at 26.06% in Q4 2023.
• A 5-year average of 4.81% and a median of 3.79% in 2024 frame the typical range for Net Margin.
• Across the five-year window, Net Margin jumped 3389 bps in 2022 and tumbled 3932 bps in 2023, its largest moves.
• Over 5 years, Net Margin stood at 13.25% in 2022, then slumped by 297 bps to 26.06% in 2023, then gained by 19 bps to 21.22% in 2024, then soared by 47 bps to 11.14% in 2025, then climbed by 24 bps to 8.52% in 2026.
• The last three Net Margin figures came in at 8.52% (Q2 2026), 9.54% (Q1 2026), and 11.14% (Q4 2025), per Business Quant data.